Luteinizing Hormone-Releasing Hormone Analog

Phase 3Small molecule

Luteinizing Hormone-Releasing Hormone Analog is one of 30 small molecule programs targeting Cancer of the Prostate. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer of the ProstateActive, not recruiting

Prostate CancerActive, not recruiting

Cancer of the ProstatePhase 3

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 2

Antiandrogen Therapy

UUniversity of Washington

Phase 3

10 3

AAA817

Novartis

Phase 3

1 4

Luteinizing Hormone-Releasing Hormone Analog

ZZhujiang Hospital

Phase 3

2 5

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

1 6

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 7

Trexall

Jazz Pharmaceuticals

Preclinical

—8

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 9

Duragesic

CCephalon

Preclinical

1 10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

Cancer of the Prostate

NCT04136353

Q4 2028

Phase 2Active, not recruiting

Prostate Cancer

NCT06734130

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

Recruiting·ZZhujiang Hospital·N/A·NCT05740488·30 enrolled

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06734130·25 enrolled

Metastatic Prostate Cancer1 trial

The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer

Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04992026·130 enrolled

Cancer of the Prostate1 trial

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting·UUniversity of Sydney·Phase 3·NCT04136353·1,100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Luteinizing Hormone-Releasing Hormone Analog. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Luteinizing Hormone-Releasing Hormone Analog compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Luteinizing Hormone-Releasing Hormone Analog. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhujiang Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZhujiang Hospital

Luteinizing Hormone-Releasing Hormone Analog

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

Prostate Cancer2 trials

Metastatic Prostate Cancer1 trial

Cancer of the Prostate1 trial

References

Drug Info

Quick Facts

Related News